UNSPSC 51162630: Meprotixol

This classification denotes an antitussive agent with the molecular formula C19H23NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2JXZ154Z0Q, chemically known as 9h-thioxanthen-9-ol, 9-(3-(dimethylamino)propyl)-2-methoxy- but more generally known as meprotixol, which bears US NIH Compound Identifier 71195. European Medicines Agency schedules Meprotixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08759MIG. The term MEPROTIXOL is an International Non-Proprietary Name.

UNSPSC 51162630 Meprotixol is a Commodity code that encompasses pharmaceutical procurement by state and local health agencies, though recent activity under this code shows limited direct relevance to meprotixol itself. The recent solicitations tagged to this code involve naloxone (a rescue medication for opioid overdose) and generic multi-source pharmaceuticals distributed through state and local health systems, indicating that the code captures a broader pharmaceutical-supply function than the specific active ingredient alone. State and local buyers using this code include county health departments, state health agencies, and multistate cooperative purchasing vehicles. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing bodies in the most recent opportunities, suggesting that both individual jurisdictions and regional purchasing consortia solicit pharmaceutical products under similar taxonomies.

The geographic spread reflects activity in Florida and Minnesota, with MMCAP's RFP explicitly extending to participating members in Oregon and potentially beyond. Seminole County's IFB (Solicitation Number IFB60459723LAS), posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, and a response deadline of July 26, 2026. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (Solicitation Number S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, with responses due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Both opportunities require detailed product compliance documentation, maintenance of authorized distributor relationships, and adherence to FDA and supply-chain security standards; the MMCAP RFP emphasizes price competitiveness (75 percent evaluation weight) and cGMP and DSCSA certification.